Compass Therapeutics reported a FY 2025 net loss of USD 66.5 million and a net loss per share of USD 0.42. R&D expenses rose 32% to USD 56.0 million, while G&A expenses increased 12% to USD 16.9 million. The company ended FY 2025 with USD 209 million in cash and marketable securities, which it expects will fund operations into 2028. On the pipeline, Compass Therapeutics said the prespecified 80% overall survival event threshold was reached in Q1 2026 in the Phase 2/3 COMPANION-002 study of tovecimig in biliary tract cancer, with progression-free survival and overall survival analyses expected to be reported in April. For CTX-8371, expansion cohorts are open in triple-negative breast cancer (n=28) and non-small cell lung cancer (n=28), with an additional Hodgkin lymphoma cohort (n=12) expected to begin shortly; initial expansion data are expected at a major medical conference in Q2 2026. The FDA cleared the IND for CTX-10726, with a Phase 1 study expected to open for enrollment in Q1 2026, and the company also said it promoted Bing Gong to Chief Scientific Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050730PRIMZONEFULLFEED9665197) on March 05, 2026, and is solely responsible for the information contained therein.
Comments